Restoration of spatial memory dysfunction of human APP transgenic mice by transplantation of neuronal precursors derived from human iPS cells

Fujiwara, Naruyoshi; Shimizu, Jun; Takai, Kenji; Arimitsu, Nagisa; Saito, Asako; Kono, Takao; Umehara, Tsuyoshi; Ueda, Y.; Wakisaka, Sueshige; Suzuki, Tomoko; Suzuki, Noboru

doi:10.1016/j.neulet.2013.10.043

Cited by 62 publications

(53 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first AD model using iPSCs was generated using five transcription factors (OCT4, SOX2, KLF4, LIN28, and NANOG) from fibroblasts of FAD patients; these iPSCs were then differentiated into neurons that may increase Aβ-42 expression to mimic Aβ pathology; thus, these iPSCs could represent a potential strategy for the development of therapeutic drugs against AD (Yagi et al 2011). For example, the intra-hippocampal transplantation of human iPSCderived cholinergic NPCs into a transgenic AD mouse model improved spatial memory performance by generating mature cholinergic neurons (Fujiwara et al 2013). In addition, iPSCs could be used to generate NEPsecreting macrophages (Takamatsu et al 2014).…”

Section: Induced Pluripotent Stem Cells (Ipscs)mentioning

confidence: 99%

Stem cells as a promising therapeutic approach for Alzheimer’s disease: a review

Fouad

2019

Bull Natl Res Cent

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a neurodegenerative disorder that impairs memory formation and disrupts neurocognitive function. This neuropathy is characterized by neural loss, neurodegeneration, and formation of amyloid plaques and neurofibrillary tangles. Approved medications provide only symptomatic relief without affecting AD progression. Because of the multifactorial nature of AD and the absence of effective treatment, stem cell-based therapy has been regarded as an effective, safe, and innovative therapeutic approach to overcome AD. Different sources of stem cells are employed for AD treatment, such as neural stem cells (NSCs), mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs). There is a growing body of evidence supporting the promising therapeutic potential of stem cell transplantation, which might be attributed to the mechanistic actions exerted by stem cells such as inducing hippocampal neurogenesis, secreting paracrine factors, exerting anti-inflammatory activity, showing anti-amyloidogenic potential, and finally resulting in cognitive recovery. Although stem cell-based therapy faces potential hurdles, it holds a potential hope to provide a safe, effective, and feasible clinical application of stem cells in AD patients.

show abstract

Section: Induced Pluripotent Stem Cells (Ipscs)mentioning

confidence: 99%

Stem cells as a promising therapeutic approach for Alzheimer’s disease: a review

Fouad

2019

Bull Natl Res Cent

View full text Add to dashboard Cite

show abstract

“…One study in an ischaemic stroke rodent model demonstrated that human iPSC-derived NSCs were able to improve neurological function and reduce pro-inflammatory factors through a neurotrophin-associated bystander effect [38]. In another recent study, following intra-hippocampal transplantation into a transgenic AD mouse model, human iPSC-derived cholinergic neuronal precursors survived, differentiated into phenotypically mature cholinergic neurons, and reversed spatial memory impairment [39]. …”

Section: Introductionmentioning

confidence: 99%

Alzheimer’s disease, dementia, and stem cell therapy

2017

View full text Add to dashboard Cite

Alzheimer’s disease (AD) represents arguably the most significant social, economic, and medical crisis of our time. Characterized by progressive neurodegenerative pathology, AD is first and foremost a condition of neuronal and synaptic loss. Repopulation and regeneration of depleted neuronal circuitry by exogenous stem cells is therefore a rational therapeutic strategy. This review will focus on recent advances in stem cell therapies utilizing animal models of AD, as well as detailing the human clinical trials of stem cell therapies for AD that are currently undergoing development.

show abstract

“…Interestingly, it has been found that in vivo use of the glial cells derived from iPSCs‐generated from mouse skin fibroblasts induced a reduction in plaque aggregation in the 5XFAD transgenic AD mouse model, as well as resolved cognitive dysfunction, partially (Cha et al, 2017). Finally, Fujiwara and his colleagues showed an improvement in memory impairments of the transgenic mice with severe amyloid β aggregation and advanced spatial memory dysfunction following transplantation of cholinergic neurons derived from human iPSCs into the hippocampus of these mice (Fujiwara et al, 2013).…”

Section: Ipscs For Cell‐based Therapy Of Neurodegenerative Diseasesmentioning

confidence: 99%

Induced pluripotent stem cells (iPSCs) as game‐changing tools in the treatment of neurodegenerative disease: Mirage or reality?

Yousefi

Abdollahii

Kouhbanani

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Based on investigations, there exist tight correlations between neurodegenerative diseases' incidence and progression and aberrant protein aggregreferates in nervous tissue. However, the pathology of these diseases is not well known, leading to an inability to find an appropriate therapeutic approach to delay occurrence or slow many neurodegenerative diseases' development. The accessibility of induced pluripotent stem cells (iPSCs) in mimicking the phenotypes of various late‐onset neurodegenerative diseases presents a novel strategy for in vitro disease modeling. The iPSCs provide a valuable and well‐identified resource to clarify neurodegenerative disease mechanisms, as well as prepare a promising human stem cell platform for drug screening. Undoubtedly, neurodegenerative disease modeling using iPSCs has established innovative opportunities for both mechanistic types of research and recognition of novel disease treatments. Most important, the iPSCs have been considered as a novel autologous cell origin for cell‐based therapy of neurodegenerative diseases following differentiation to varied types of neural lineage cells (e.g. GABAergic neurons, dopamine neurons, cortical neurons, and motor neurons). In this review, we summarize iPSC‐based disease modeling in neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease. Moreover, we discuss the efficacy of cell‐replacement therapies for neurodegenerative disease.

show abstract

Restoration of spatial memory dysfunction of human APP transgenic mice by transplantation of neuronal precursors derived from human iPS cells

Cited by 62 publications

References 22 publications

Stem cells as a promising therapeutic approach for Alzheimer’s disease: a review

Stem cells as a promising therapeutic approach for Alzheimer’s disease: a review

Alzheimer’s disease, dementia, and stem cell therapy

Induced pluripotent stem cells (iPSCs) as game‐changing tools in the treatment of neurodegenerative disease: Mirage or reality?

Contact Info

Product

Resources

About